Demographic and clinicopathological characteristics
Table 1 summarizes the baseline characteristics of patients with CHC who underwent TACE (n=46) and those who did not (n=184) before PSM. The mean age of patients in the TACE group (52±10.7 years) was similar to that of patients in the non-TACE group (52.3±12.1 years), and the sex distribution was similar in both groups (38 and 134 male patients in the TACE group and non-TACE group, respectively). The median AFP (p= 0.006), median bilirubin (p< 0.001), occlusion time (p= 0.044), and macrovascular invasion (p= 0.041) were higher in the TACE group than in the non-TACE group, and the median CA19-9 was higher in the non-TACE group than in the TACE group (p= 0.029). After PSM, the mean age of patients in the TACE group (52±10.7 years) was similar to that of patients in the non-TACE group (53.4±11.6 years), and the sex distribution was similar in both groups. Except for the higher median AFP (p= 0.006), lower median CA19-9 (p= 0.023), lower median bilirubin (<0.001), lower mean occlusion time (p= 0.044), and macrovascular invasion (p= 0.041) in the TACE group, there were no significant differences between the TACE group and the non-TACE group in terms of the baseline characteristics (p> 0.05).
Table 1. Preoperative clinicopathologic Data of Patients with CHC Who received or not postoperative TACE.
Variable
|
Before Propensity Matching
|
After Propensity Matching
|
Without TACE (n=184)
|
Postoperative TACE (n=46)
|
P
|
Without TACE (n=46)
|
Postoperative TACE (n=46)
|
P
|
Sex
|
|
|
0.172
|
|
|
>0.99
|
Men
|
134
|
38
|
|
38
|
38
|
|
Women
|
50
|
8
|
|
8
|
8
|
|
Mean age (y)
|
52.3±12.1
|
52±10.7
|
0.326
|
53.4±11.6
|
52±10.7
|
0.834
|
HBsAg
|
|
|
>0.99
|
|
|
0.810
|
Positive
|
136
|
34
|
|
35
|
34
|
|
Negative
|
48
|
12
|
|
11
|
12
|
|
HBcAb
|
|
|
0.666
|
|
|
0.231
|
Positive
|
153
|
9
|
|
42
|
9
|
|
Negative
|
31
|
37
|
|
4
|
37
|
|
HCV antibody
|
|
|
>0.99
|
|
|
>0.99
|
Positive
|
4
|
1
|
|
1
|
1
|
|
Negative
|
180
|
45
|
|
45
|
45
|
|
Median AFP, ng/mL
|
24.7 (1-80000)
|
96 (1.8-46897)
|
0.006
|
21.3 (1-30728)
|
96 (1.8-46897)
|
0.002
|
Median CEA, μg/mL
|
2.5 (0-274)
|
2.1 (0.5-70.5)
|
0.364
|
2.7 (0.1-112.4)
|
2.1 (0.5-70.5)
|
0.423
|
Median CA19-9, U/ml
|
28.1 (0-4370)
|
19.4 (0.2-300.1)
|
0.029
|
22 (0.5-4062.5)
|
19.4 (0.2-300.1)
|
0.023
|
Median bilirubin, μmol/L
|
11.8 (1.7-314.8)
|
12.9 (5.7-156.5)
|
<0.001
|
13.7 (2.4-169.3)
|
12.9 (5.7-156.5)
|
0.664
|
Median albumin, g/L
|
41 (26-55)
|
42 (35-66)
|
0.397
|
41 (30-48)
|
42 (35-66)
|
0.556
|
Median ALT, U/L
|
28 (5-484)
|
31 (5-104)
|
0.094
|
26 (11-484)
|
31 (5-104)
|
0.109
|
Median ALP, IU/L
|
89.5 (22-1413)
|
88.5 (46-184)
|
0.477
|
92 (25-331)
|
88.5 (46-184)
|
0.599
|
Median GGT, U/L
|
59 (3.6-1632)
|
80 (18-490)
|
0.923
|
75.5 (10-658)
|
80 (18-490)
|
0.273
|
Median platelets, 103/μL
|
13.7 (2.2-47.6)
|
16 (3.9-46.1)
|
0.319
|
15.3 (5.3-24.7)
|
16 (3.9-46.1)
|
0.171
|
Median prothrombin time, s
|
11.8 (9-17.6)
|
12 (10.2-13.8)
|
0.941
|
12 (10.2-14.6)
|
12 (10.2-13.8)
|
0.903
|
Median INR
|
1 (0.5-1.5)
|
1 (0.8-1.2)
|
0.227
|
1 (0.5-1.2)
|
1 (0.8-1.2)
|
0.065
|
Median tumour size, cm
|
5 (1-24)
|
7.3 (1.5-17)
|
0.626
|
6 (1.5-22)
|
7.3 (1.5-17)
|
0.384
|
Median tumour nodularities
|
1 (1-10)
|
1 (1-5)
|
0.140
|
1 (1-6)
|
1 (1-5)
|
0.648
|
Median blood loss, ml
|
200 (30-3500)
|
200 (10-2500)
|
0.182
|
200 (50-1800)
|
200 (10-2500)
|
0.480
|
Mean occlusion, min
|
6.8±8.6
|
10±1.6
|
0.044
|
5.4±1.1
|
10±1.6
|
0.090
|
Macrovascular invasion
|
|
|
0.041
|
|
|
>0.99
|
Positive
|
11
|
7
|
|
7
|
7
|
|
Negative
|
173
|
39
|
|
39
|
39
|
|
Microvascular invasion
|
|
|
0.689
|
|
|
0.607
|
Positive
|
39
|
11
|
|
8
|
11
|
|
Negative
|
145
|
35
|
|
38
|
35
|
|
Lymphoid metastasis
|
|
|
0.840
|
|
|
>0.99
|
Positive
|
22
|
6
|
|
6
|
6
|
|
Negative
|
162
|
40
|
|
40
|
40
|
|
Extrahepatic metastasis
|
|
|
0.719
|
|
|
0.646
|
Positive
|
6
|
2
|
|
3
|
2
|
|
Negative
|
178
|
44
|
|
43
|
44
|
|
Postrecurrent therapy
|
|
|
0.451
|
|
|
0.583
|
Resection
|
2
|
1
|
|
1
|
1
|
|
TACE
|
27
|
6
|
|
10
|
6
|
|
Regional therapy
|
4
|
1
|
|
1
|
1
|
|
Chemothearpy
|
66
|
14
|
|
11
|
14
|
|
Selective internal radiation therapy
|
5
|
2
|
|
1
|
2
|
|
Stereotactic body radiation
|
12
|
5
|
|
3
|
5
|
|
Best supportive care
|
58
|
17
|
|
19
|
17
|
|
Note: data are numbers of patients. Data in parentheses are range. Mean data are±standard deviation. Regional therapy: Radiofrequency ablation and percutaneous ethanol injection.
HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; HCV, hepatitis C virus; AFP, α-fetoprotein; CEA, carcino-embryonic antigen; CA19-9, carbohydrate 19-9; INR, International normalized ratio; ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase; MVI, microvascular vascular invasion.
OS and DFS before PSM
The median survival of the whole cohort was 22.6 months, and the overall cumulative OS rates at 1, 3, 5, and 10 years were 48.5%, 33.3%, 25.8%, and 15.3%, respectively. The median OS of the TACE group and non-TACE group was 22.0 months and 23.5 months, respectively. The cumulative OS rates were comparable between the two groups; the 1-, 3-, 5-, and 10-year OS rates in the TACE group were 46.6%, 31.7%, 22.7%, and 12.6%, respectively, whereas those in the non-TACE group were 49.0%, 33.7%, 26.6%, and 16.1%, respectively (p=0.34) (Fig. 2A). The median DFS of the whole cohort was 14.0 months, and the cumulative DFS rates at 1, 3, 5, and 10 years were 20.9%, 10.4%, 0.7%, and 0.3%, respectively. Stratified by TACE, the median DFS in the TACE group was less than that in the non-TACE group (9.3 months vs. 17.2 months) (p =0.001) (Fig. 2B).
The prognostic factors of CHC before PSM
To identify potential confounders, we used the Cox proportional hazards model to analyse the risk factors for CHC. For OS, in univariate analysis, the following six variants were enrolled in the multivariate analysis: γ-GT (p <0.001), tumour size (p =0.002), tumour nodularities (p =0.003), macrovascular invasion (p <0.001), lymphoid metastasis (p <0.001), and extrahepatic metastasis (p <0.001). In multivariate analysis, γ-GT (p =0.001), tumour nodularities (p =0.031), macrovascular invasion (p <0.001), lymphoid metastasis (p =0.008), and extrahepatic metastasis (p <0.001) were independent factors of OS (Table 2).
Table 2. Univariable and multivariable cox analysis of OS before propensity matched analysis
Variable
|
Univariable
|
Multivariable
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
Age (≥60/<60, year)
|
1.279
|
0.857-1.908
|
0.229
|
---
|
---
|
---
|
Sex (Men/Women)
|
1.443
|
0.95-2.193
|
0.085
|
---
|
---
|
---
|
HBsAg (yes/no)
|
1.044
|
0.719-1.517
|
0.821
|
---
|
---
|
---
|
HCV antibody (yes/no)
|
2.293
|
0.722-7.283
|
0.159
|
---
|
---
|
---
|
AFP (≥20/<20, ng/mL)
|
2.819
|
0.68-11.682
|
0.153
|
---
|
---
|
---
|
CEA (≥5/<5, ng/mL)
|
1.844
|
0.643-5.29
|
0.255
|
---
|
---
|
---
|
CA19-9 (≥37/<37, U/mL)
|
2.069
|
0.639-6.702
|
0.225
|
---
|
---
|
---
|
Liver cirrhosis, yes (%)
|
1.252
|
0.857-1.83
|
0.245
|
---
|
---
|
---
|
TB (≥17/<17, μmol/L)
|
0.950
|
0.626-1.443
|
0.810
|
---
|
---
|
---
|
ALB (≥40/<40, g/mL)
|
0.759
|
0.530-1.086
|
0.132
|
---
|
---
|
---
|
ALT (≥35/<35, U/L)
|
1.327
|
0.941-1.870
|
0.106
|
---
|
---
|
---
|
γ-GT (≥40/<40, U/L)
|
2.662
|
1.703-4.163
|
<0.001
|
2.152
|
1.354-3.421
|
0.001
|
PLT (≥10/<10 103/μL)
|
1.005
|
0.665-1.518
|
0.982
|
---
|
---
|
---
|
Prothrombin time, median (range), s
|
1.199
|
0.781-1.841
|
0.406
|
---
|
---
|
---
|
Tumour size, cm
|
1.769
|
1.235-2.534
|
0.002
|
1.274
|
0.867-1.872
|
0.218
|
Tumour nodularities
|
1.167
|
1.055-1.292
|
0.003
|
1.130
|
1.011-1.262
|
0.031
|
Occlusion, min (<20/≥20)
|
0.290
|
0.740-2.250
|
0.369
|
---
|
---
|
---
|
Macrovascular invasion (yes/no)
|
1.927
|
1.442-2.576
|
<0.001
|
1.869
|
1.375-2.540
|
<0.001
|
Microvascular invasion (yes/no)
|
1.365
|
0.921-2.204
|
0.122
|
---
|
---
|
---
|
Lymphoid metastasis (yes/no)
|
2.801
|
1.745-4.495
|
<0.001
|
2.031
|
1.201-3.435
|
0.008
|
Extrahepatic metastasis (yes/no)
|
11.435
|
5.262-24.849
|
<0.001
|
6.392
|
2.731-14.961
|
<0.001
|
Preventive TACE (yes/no)
|
1.212
|
0.807-1.821
|
0.354
|
---
|
---
|
---
|
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, α-fetoprotein; CEA, carcino-embryonic antigen; CA19-9, carbohydrate 19-9; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transpeptidase; PLT, platelet; ALP, alkaline phosphatase.
For DFS, in univariate analysis, the following five variants were enrolled in the multivariate analysis: male sex (p =0.034), ALT (p =0.008), γ-GT (p =0.016), occlusion time (p =0.002), macrovascular invasion (p =0.001), lymphoid metastasis (p =0.005), and preventive TACE (p <0.001). In multivariate analysis, we found that ALT (p = 0.031), macrovascular invasion (p =0.001), lymphoid metastasis (p = 0.001), and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p <0.001) were independent prognostic factors of DFS (Table 3).
Table 3. Univariable and multivariable cox analysis of DFS before propensity matched analysis
Variable
|
Univariable
|
Multivariable
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
Age (≥60/<60, year)
|
1.240
|
0.765-2.010
|
0.382
|
---
|
---
|
---
|
Sex (Men/Women)
|
1.751
|
1.042-2.941
|
0.034
|
1.919
|
1.097-3.357
|
0.022
|
HBsAg (yes/no)
|
0.672
|
0.405-1.114
|
0.123
|
---
|
---
|
---
|
HCV antibody (yes/no)
|
0.782
|
0.108-5.636
|
0.807
|
---
|
---
|
---
|
AFP (≥20/<20, ng/mL)
|
1.245
|
0.824-1.881
|
0.299
|
---
|
---
|
---
|
CEA (≥5/<5, ng/mL)
|
1.169
|
0.672-2.035
|
0.581
|
---
|
---
|
---
|
CA19-9 (≥37/<37, U/mL)
|
1.136
|
0.727-1.775
|
0.575
|
---
|
---
|
---
|
Liver cirrhosis, yes (%)
|
1.291
|
0.815-2.044
|
0.277
|
---
|
---
|
---
|
TB (≥17/<17, μmol/L)
|
0.998
|
0.607-1.641
|
0.995
|
---
|
---
|
---
|
ALB (≥40/<40, g/mL)
|
0.771
|
0.499-1.191
|
0.241
|
---
|
---
|
---
|
ALT (≥35/<35, U/L)
|
1.741
|
1.154-2.267
|
0.008
|
1.676
|
1.050-2.677
|
0.031
|
γ-GT (≥40/<40, U/L)
|
1.811
|
1.116-2.938
|
0.016
|
1.105
|
0.653-1.870
|
0.711
|
PLT (≥10/<10 103/μL)
|
0.856
|
0.529-1.382
|
0.524
|
---
|
---
|
---
|
Prothrombin time, median (range), s
|
1.417
|
0.845-2.375
|
0.186
|
---
|
---
|
---
|
Tumour size, cm
|
1.226
|
0.809-1.857
|
0.338
|
---
|
---
|
---
|
Tumour nodularities
|
1.056
|
0.918-1.215
|
0.442
|
---
|
---
|
---
|
Occlusion, min (<20/≥20)
|
2.363
|
1.356-4.119
|
0.002
|
1.790
|
0.974-3.289
|
0.061
|
Macrovascular invasion (yes/no)
|
1.878
|
1.300-2.713
|
0.001
|
2.026
|
1.342-3.058
|
0.001
|
Microvascular invasion (yes/no)
|
1.084
|
0.654-1.797
|
0.754
|
---
|
---
|
---
|
Lymphoid metastasis (yes/no)
|
2.300
|
1.287-4.112
|
0.005
|
2.835
|
1.517-5.297
|
0.001
|
Extrahepatic metastasis (yes/no)
|
2.248
|
0.538-9.395
|
0.267
|
---
|
---
|
---
|
Preventive TACE (yes/no)
|
2.799
|
1.815-4.317
|
<0.001
|
2.763
|
1.769-4.314
|
<0.001
|
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, α-fetoprotein; CEA, carcino-embryonic antigen; CA19-9, carbohydrate 19-9; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transpeptidase; PLT, platelet; ALP, alkaline phosphatase.
PSM for TACE and non-TACE patients
The distribution of the risk factors and demographic characteristics differed between the TACE and non-TACE groups. To reduce confounding factors and to reflect the true effect of TACE, we established a PSM model based on the analysis of the risk factors described above. Considering OS and DFS, four variates were involved in the model: AFP, CA19-9, total bilirubin, and macrovascular invasion. Finally, we matched 46 pairs of TACE and non-TACE patients. Apart from AFP and CA19-9, all other variables were balanced between the two groups (all p >0.2). The balances between the two groups are shown in Table 1.
OS and DFS after PSM
After PSM, the median OS of the TACE group and non-TACE group was 22.0 months and 16.3 months, respectively. The cumulative survival rates in the TACE group at 1, 3, 5, and 10 years were 46.6%, 31.7%, 22.7%, and 12.6%, respectively, whereas those in the non-TACE group were 36.4%, 22.4%, 14.9%, and 14.9%, respectively. However, the OS between the TACE and non-TACE groups was still comparable after PSM (p =0.75) (Fig. 2C). The median DFS of the TACE group and non-TACE group was 7.3 months and 10.0 months, respectively. The cumulative DFS rates in the TACE group at 1, 3, 5, and 10 years were 20.8%, 14.9%, 11.2%, and 5.6%, respectively, whereas those in the non-TACE group were 28.7%, 14.4%, 14.4%, and 14.4%, respectively. However, the DFS between the TACE and non-TACE groups was comparable after PSM (p =0.06) (Fig. 2D).
The prognostic factors of CHC after PSM
After PSM, for OS, in univariate analysis, the following three variants were enrolled in the multivariate analysis: HCV antibody (p =0.013), macrovascular invasion (p <0.001), and extrahepatic metastasis (p <0.001). In multivariate analysis, HCV antibody (p =0.004), macrovascular invasion (p =0.001), and extrahepatic metastasis (p <0.001) were independent factors of OS (Table 4).
For DFS, in univariate analysis, the following four variants were enrolled in the multivariate analysis: ALT (p =0.02), occlusion time (p =0.005), macrovascular invasion (p =0.002), and preventive TACE (p =0.001). In multivariate analysis, macrovascular invasion (p =0.006) and preventive TACE (HR: 3.345, 95% CI: 1.686-6.638, p= 0.001) were independent factors of DFS.
Table 4. Univariable and multivariable cox analysis of OS after propensity matched analysis
Variable
|
Univariable
|
Univariable
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
Age (≥60/<60, year)
|
0.922
|
0.463-1.837
|
0.818
|
---
|
---
|
---
|
Sex (Men/Women)
|
1.458
|
0.689-3.087
|
0.324
|
---
|
---
|
---
|
HBsAg (yes/no)
|
1.711
|
0.887-3.300
|
0.109
|
---
|
---
|
---
|
HCV antibody (yes/no)
|
6.405
|
1.491-27.524
|
0.013
|
9.142
|
2.028-41.225
|
0.004
|
AFP (≥20/<20, ng/mL)
|
1.288
|
0.761-2.181
|
0.346
|
---
|
---
|
---
|
CEA (≥5/<5, ng/mL)
|
1.643
|
0.924-2.923
|
0.091
|
---
|
---
|
---
|
CA19-9 (≥37/<37, U/mL)
|
1.591
|
0.932-2.715
|
0.089
|
---
|
---
|
---
|
Liver cirrhosis, yes (%)
|
1.952
|
1.091-3.493
|
1.379
|
6.264
|
0.734-2.590
|
0.318
|
TB (≥17/<17, μmol/L)
|
0.739
|
0.383-1.427
|
0.368
|
---
|
---
|
---
|
ALB (≥40/<40, g/mL)
|
0.814
|
0.476-1.391
|
0.451
|
---
|
---
|
---
|
ALT (≥35/<35, U/L)
|
1.459
|
0.869-2.452
|
0.153
|
---
|
---
|
---
|
γ-GT (≥40/<40, U/L)
|
1.811
|
0.933-3.515
|
0.079
|
---
|
---
|
---
|
PLT (≥10/<10 103/μL)
|
1.353
|
0.683-2.682
|
0.386
|
---
|
---
|
---
|
Prothrombin time, median (range), s
|
1.014
|
0.547-1.880
|
0.964
|
---
|
---
|
---
|
Tumour size, cm
|
1.466
|
0.814-2.639
|
0.203
|
---
|
---
|
---
|
Tumour nodularities
|
1.017
|
0.785-1.318
|
0.898
|
---
|
---
|
---
|
Occlusion, min (<20/≥20)
|
1.560
|
0.735-3.310
|
0.247
|
---
|
---
|
---
|
Macrovascular invasion (yes/no)
|
3.343
|
1.770-6.315
|
<0.001
|
3.035
|
1.543-5.972
|
0.001
|
Microvascular invasion (yes/no)
|
1.359
|
0.725-2.546
|
0.338
|
---
|
---
|
---
|
Lymphoid metastasis (yes/no)
|
1.487
|
0.667-3.315
|
0.332
|
---
|
---
|
---
|
Extrahepatic metastasis (yes/no)
|
6.805
|
2.549-18.166
|
<0.001
|
6.264
|
2.277-17.235
|
<0.001
|
Preventive TACE (yes/no)
|
0.911
|
0.545-1.520
|
0.720
|
---
|
---
|
---
|
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, α-fetoprotein; CEA, carcino-embryonic antigen; CA19-9, carbohydrate 19-9; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transpeptidase; PLT, platelet; ALP, alkaline phosphatase.
Table 5. Univariable and multivariable cox analysis of DFS after propensity matched analysis
Variable
|
Univariable
|
Multivariable
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
Age (≥60/<60, year)
|
1.198
|
0.587-2.443
|
0.620
|
---
|
---
|
---
|
Sex (Men/Women)
|
1.827
|
0.713-4.685
|
0.209
|
---
|
---
|
---
|
HBsAg (yes/no)
|
1.478
|
0.706-3.096
|
0.300
|
---
|
---
|
---
|
HCV antibody (yes/no)
|
0.048
|
0.526-4.934
|
0.665
|
---
|
---
|
---
|
AFP (≥20/<20, ng/mL)
|
1.075
|
0.585-1.976
|
0.815
|
---
|
---
|
---
|
CEA (≥5/<5, ng/mL)
|
0.820
|
0.380-1.771
|
0.614
|
---
|
---
|
---
|
CA19-9 (≥37/<37, U/mL)
|
1.019
|
0.520-1.997
|
0.957
|
---
|
---
|
---
|
Liver cirrhosis, yes (%)
|
1.436
|
0.752-2.744
|
0.273
|
---
|
---
|
---
|
TB (≥17/<17, μmol/L)
|
0.941
|
0.449-1.973
|
0.873
|
---
|
---
|
---
|
ALB (≥40/<40, g/mL)
|
0.580
|
0.315-1.068
|
0.080
|
---
|
---
|
---
|
ALT (≥35/<35, U/L)
|
2.083
|
1.120-3.873
|
0.020
|
1.989
|
0.980-4.037
|
0.057
|
γ-GT (≥40/<40, U/L)
|
1.265
|
0.616-2.597
|
0.521
|
---
|
---
|
---
|
PLT (≥10/<10 103/μL)
|
0.975
|
0.466-2.043
|
0.947
|
---
|
---
|
---
|
Prothrombin time, median (range), s
|
1.841
|
0.942-3.598
|
0.074
|
---
|
---
|
---
|
Tumour size, cm
|
1.077
|
0.560-2.071
|
0.823
|
---
|
---
|
---
|
Tumour nodularities
|
0.992
|
0.731-1.346
|
0.957
|
---
|
---
|
---
|
Occlusion, min (<20/≥20)
|
3.308
|
1.388-6.647
|
0.005
|
1.565
|
0.639-3.833
|
0.327
|
Macrovascular invasion (yes/no)
|
3.703
|
1.607-8.535
|
0.002
|
3.361
|
1.416-7.977
|
0.006
|
Microvascular invasion (yes/no)
|
1.705
|
0.854-3.407
|
0.131
|
---
|
---
|
---
|
Lymphoid metastasis (yes/no)
|
1.423
|
0.553-3.663
|
0.464
|
---
|
---
|
---
|
Extrahepatic metastasis (yes/no)
|
2.246
|
0.520-9.712
|
0.279
|
---
|
---
|
---
|
Preventive TACE (yes/no)
|
3.144
|
1.610-6.137
|
0.001
|
3.345
|
1.686-6.638
|
0.001
|
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, α-fetoprotein; CEA, carcino-embryonic antigen; CA19-9, carbohydrate 19-9; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transpeptidase; PLT, platelet; ALP, alkaline phosphatase; NS, non-sense.